Home / Healthcare / Dilated Cardiomyopathy Therapeutics Market By Treatment (Drug Class, Implantable Device) - Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026

Dilated Cardiomyopathy Therapeutics Market By Treatment (Drug Class, Implantable Device) - Growth, Share, Opportunities & Competitive Analysis, 2018 – 2026


Published: Nov 2018

Industry Outlook

The dilated cardiomyopathy therapeutics market is set to reach US$ xx Mn by 2026 from US$ xx Mn in 2017 featuring magnificent growth at a compounded annual growth rate (CAGR) of 4.7% during the forecast period from 2018 to 2026. As per the latest research citings of World Health Organization (WHO), annually 17.9 million people die throughout the globe from cardiovascular diseases which is equivalent o 31% of all global deaths. Factors responsible for congestive heart failure are sedentary lifestyle, obesity, unhealthy lifestyle and congenital heart complications.

Pharmaceuticals companies are striving earnestly to manufacture drugs with least possible side effects and desired therapeutic efficacy. Drugs in Phase III clinical trials showing promising results are enalapril orodispersible minitablets (Ethicare GmbH), ARRY-371797 (Array BioPharma) and ixCELL-DCM (Vericel Corporation).

"Excellent clinical outcomes and satisfactory patient compliance makes drug class the most viable treatment option for dilated cardiomyopathy"

In the current scenario drug class are reigning the treatment segment for dilated cardiomyopathy therapeutics market. The parameters responsible for the growth of drug class are increasing number of patients diagnosed with congestive heart failure. Moreover excellent clinical outcomes and satisfactory patient compliance make drug class the most viable option for the treatment of dilated cardiomyopathy. Angiotensin converting enzyme inhibitors (ACE inhibitors) are considered as first line of drug therapy due to its positive clinical effects such as relaxing heart muscles and promoting blood flow. Angiotensin receptor blockers are given with diuretics to patients that do not tolerate ACE inhibitors. They help to regulate the blood flow by widening of blood vessels and reducing the fluid in lungs and kidneys. Beta blockers and anticoagulants are prescribed to reduce the pressure on the heart valves and prevent blood clotting in the heart chambers due to inability of the weakened left ventricular muscles to pump the blood. Implantable devices are gaining traction owing to the side effects associated with drug class and long term benefit provided by devices such as heart pumps, biventricular pacemakers and implantable cardioveter-defibrillators.

"Rising prevalence of congestive heart failure drive the dilated cardiomyopathy therapeutics market growth in North America"

North America is currently leading the geography segment for dilated cardiomyopathy therapeutics market owing to factors such as rising prevalence of congestive heart failure. According to the facts presented by Center for Disease Control and Prevention (CDC) in United States approximately 610,000 people die of heart disease annually. Existence of well-developed healthcare infrastructure and affordable reimbursement scenario drive the dilated cardiomyopathy market growth in North America. As per the latest research citings of European Heart Network (EHN) every year 3.9 million people die in Europe amounting to 45% of all deaths caused in the region. Domicile of major players such as Merck & Co., Inc., GlaxoSmithKline Plc and t2cure GmbH etc., propel the market growth in European Union region.  Asia Pacific will register outstanding growth during the forecast period on account of rising prevalence of congenital heart diseases, favorable regulatory scenario and growing medical tourism due to affordable treatment cost. Latin America and Middle East & Africa serve as a potential market to promote business expansion opportunities by establishing subsidiaries and retail outlets for major players proving treatment option for dilated cardiomyopathy.

Historical & Forecast Period

This research report presents the analysis of each segment from 2016 to 2026 considering 2017 as the base year for the research. Compounded annual growth rate (CAGR) for each respective segments are calculated for the forecast period from 2018 to 2026.

Report Scope by Segments

Market estimation and compounded annual growth rate were determined by studying the latest market trends prevalent in dilated cardiomyopathy therapeutics market. The market is subsegmented as by treatment and regional segment.

ATTRIBUTE DETAILS
Research Period  2016-2026
Base Year 2017
Forecast Period  2018-2026
Historical Year  2016
Unit  USD Million
Segmentation

 By Treatment (2016–2026; US$ Mn)
 • Drug Class
    o Angiotensin II Receptor Blockers
    o Angiotensin-Converting Enzyme (ACE) Inhibitors
    o Beta Blockers
    o Anticoagulants
    o Digitalis
    o Diuretics
 • Implantable Device
    o Heart Pumps
    o Biventricular Pacemakers
    o Implantable Cardioverter-Defibrillators
 • Pipeline Analysis
    o Phase III Drugs
         Enalapril Orodispersible Minitablet
         ARRY-371797
         ixCELL-DCM
    o Tabular Representation of Drug Pipeline in Phase II and I

 Geography Segment (2016–2026; US$ Mn)
 • North America (United States and Canada)
 • Europe (U.K., Germany, Rest of Europe)
 • Asia Pacific (China, Japan, Rest of Asia Pacific)
 • Latin America (Brazil, Mexico, Rest of Latin America)
 • Middle East and Africa (GCC, Rest of MEA)

Pharmaceutical companies spearheading the dilated cardiomyopathy therapeutics market are Aastrom Biosciences, Capricor Therapeutics, GlaxoSmithkline Plc, Johnson and Johnson, Kasiak Research Pvt. Ltd., Merck & Co., Inc., MyoKardia, Pfizer, Inc., t2cure, GmbH, Teva Pharmaceutical Industries, ZensunSci & Tech.

Key questions answered in this report

  • What are the organic and inorganic market growth strategies employed to determine the compounded annual growth rate and market estimation?
  • Which pharmaceutical and medical device companies are engaged to provide treatment options for dilated cardiomyopathy?
  • What are the DRO’s associated with the dilated cardiomyopathy therapeutics market?
  • What is the disease etiology of dilated cardiomyopathy and treatment regimen adopted by physicians throughout the globe?
  • Which is the leading and fastest growing treatment segment for dilated cardiomyopathy therapeutics market?
  • Which is the leading and fastest growing regional segment for dilated cardiomyopathy therapeutics market?

TABLE 1 Global DCT Market (DCT) Market Portraiture
TABLE 2 Global DCT Market Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 3 Global Drug Class Market for DCT Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 4 Global Implantable Device Market for DCT Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 5 Global DCT Market Market, by Geography, 2016 – 2026 (US$ Mn)
TABLE 6 North America DCT Market Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 7 North America DCT Market Market, by Country, 2016 – 2026 (US$ Mn)
TABLE 8 Europe DCT Market Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 9 Europe DCT Market Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 10 Asia Pacific DCT Market Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 11 Asia Pacific DCT Market Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 12 Latin America DCT Market Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 13 Latin America DCT Market Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 14 Middle East and Africa DCT Market Market, by Treatment, 2016 – 2026 (US$ Mn)
TABLE 15 Middle East and Africa DCT Market Market, by Country/Region, 2016 – 2026 (US$ Mn)
TABLE 16 Aastrom Biosciences: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 17 Capricor Therapeutics: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 18 GlaxoSmithkline Plc.: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 19 Johnson and Johnson: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 20 Kasiak Research Pvt. Ltd.: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 21 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 22 Myokardia: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 23 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 24 T2cure GmbH: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 25 Teva Pharmaceuticals Industries: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)
TABLE 26 ZensunSci & tech.: Company Snapshot (Business Description; Financial Information; Treatment Portfolio; Key Developments)

Choose License Type
 
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
sales@acutemarketreports.com
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +